UNIVEC, Inc. (UNVC: OTC Link) | UNIVEC announces entry into Transdermal Patch Marketplace

UNIVEC announces entry into Transdermal Patch Marketplace

Jan 16, 2012

OTC Disclosure News Service

Owings Mills, MD –


David Dalton, President

E-mail univec@univecinc.com

UNIVEC announces entry into Transdermal Patch Marketplace.

Owings Mills, Maryland —January 17, 2012– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has entered into the transdermal patch marketplace with the provision of Nicotine Replacement Therapy patches. Nicotine Replacement Therapy involves the use of products that provide low doses of nicotine but do not contain the toxins found in smoke. The goal is to relieve cravings for nicotine and ease the symptoms when someone stops using cigarettes and smokeless tobacco. Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.


David L. Dalton, President and CEO of Univec stated. “ We are delighted to continue making progress in our new business model. The National Drug Codes received from the FDA allows Univec to builds it’s own brand of products. The Transdermal patch can be used for different drug delivery system. It is a foundation to build and grow the company on some of our existing markets. We thank our associates, shareholders and investors for the support, confidence and patience they have shown the company.


About Univec

 Univec, Inc.  A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime.  The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.


PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.


Forward Looking Statements

This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/UNVC/news?id=41371

Leave a Reply

WP2Social Auto Publish Powered By : XYZScripts.com
Bunk Beds